PLYMOUTH
MEETING, Pa., Nov. 8, 2023
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony"
or the "Company") (Nasdaq: HRMY), a pharmaceutical company
dedicated to developing and commercializing innovative
therapies for patients with rare neurological diseases, today
announced the appointment of Peter Anastasiou to the Company's
Board of Directors.
Peter is Chief Executive Officer of a development stage company
Capsida. Anastasiou held various leadership positions at Lundbeck,
where he was critical in shaping overall corporate strategy,
R&D priorities, and business development. He served as
President of North America,
overseeing the U.S. and Canadian business operations, and was U.S.
Chief Commercial Officer, directing the commercial operations of
the company's neurology and psychiatry franchises and launching new
products and indications.
"I am energized to join Harmony's Board of Directors at this
critical stage of growth for the company. The mission of bringing
new treatment options to people living with profound unmet medical
needs is a great passion to which I have dedicated my entire
professional career," said Anastasiou. "I look forward to
supporting this dedicated management team and working with the
other visionary leaders on the board of directors as we explore
opportunities to bring new treatments to people living with rare
neurological diseases."
"Peter's CNS and business development expertise will support
Harmony's growth priorities," said Harmony Biosciences Chairman
Jeff Aronin. "He brings good
experience developing and commercializing new therapeutics for
patients with unmet medical needs. Peter aligns with our mission
and priorities."
Before Lundbeck, Anastasiou held management roles at
Neuronetics, Inc., Bristol-Myers Squibb Company, and Eli Lilly. He
is actively involved in the Healthcare Businesswomen's
Association's (HBA) global advisory board, which awarded him the
2019 HBA Honorable Mentor for his work advocating for gender parity
in life science leadership.
Anastasiou holds an MBA from the Kelley School of Business
at Indiana University and a BA in
economics and management from Albion
College.
About Harmony Biosciences
At Harmony Biosciences, we specialize in developing and delivering
treatments for rare neurological diseases that others often
overlook. We believe that where empathy and innovation meet, a
better life can begin for people living with neurological diseases.
Established by Paragon Biosciences, LLC, in 2017 and headquartered
in Plymouth Meeting, PA, our team
of experts from a wide variety of disciplines and experiences is
driven by our shared conviction that innovative science translates
into therapeutic possibilities for our patients, who are at the
heart of everything we do. For more information, please visit
www.harmonybiosciences.com.
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com
Harmony Biosciences Investor Contact:
Luis Sanay, CFA
445-235-8386
lsanay@harmonybiosciences.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-appoints-peter-anastasiou-to-its-board-of-directors-301980887.html
SOURCE Harmony Biosciences